Last reviewed · How we verify
NCT03329924
ICU Liberation: Does Enhanced Patient Mobilization Improve Outcomes?
trial testing Activity level measurement by accelerometer in Early Mobilization of Mechanically Ventilated Patients in 220 participants. Completed in 1 January 2023.
1 December 2020
Quick facts
| Lead sponsor | Bassett Healthcare |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 220 |
| Start date | 1 December 2017 |
| Primary completion | 1 December 2020 |
| Estimated completion | 1 January 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Activity level measurement by accelerometer
Conditions studied
- Early Mobilization of Mechanically Ventilated Patients — all drugs for Early Mobilization of Mechanically Ventilated Patients →
Sponsor
Bassett Healthcare — full company profile →
Who can join
18 and older, any sex, with Early Mobilization of Mechanically Ventilated Patients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The hypothesis of this study is that an early mobilization program coupled with organizational efforts to implement the ABCDEF bundle will increase the rate of ICU patient mobilization and decrease the ICU length of stay, but will not significantly affect patient mortality. Mobilization efforts will be done to improve patient care and the study will allow for measurement of the effects of implementation of this effort. The early mobilization program is being instituted as standard of care. The study will measure the actual degree of change in patients' activity level and to evaluate the effect of the program on outcome measures such as length of stay.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03329924
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Bassett Healthcare trials
Trials by the same sponsor.
- NCT04474288 — The COVID-19 PUI Reality Check (CPRC) Study · completed
- NCT04328012 — COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19 · Phase 2, PHASE3 · terminated
- NCT04327791 — COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1) · Phase 2, PHASE3 · unknown
- NCT04245683 — Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population · recruiting
- NCT04180943 — Liposomal Bupivacaine Versus Bupivacaine for for Postoperative Pain Control in Shoulder Surgery · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03329924 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bassett Healthcare
- Last refreshed: 7 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03329924.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing